SCHEMBL3292015

SCHEMBL3292015

CCC(=O)c1ccc2c(c1)CN(C(=O)C(F)(F)F)CC2

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.64
ESR2 Q92731 5/20 0.64
HDAC6 Q9UBN7 4/20 0.49
HDAC8 Q9BY41 2/20 0.49
PKM P14618 1/20 0.47
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ABHD6 Q9BV23 1/20 0.44
NR1H2 P55055 1/20 0.43
MCHR1 Q99705 1/20 0.41
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MYC P01106 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6193455 0.97 ESR1 (0.61) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL1367390 0.87 ESR1 (0.64) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL1367533 0.87 ESR1 (0.64) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL31670429 0.85 ESR1 (0.68) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL4704441 0.85 ESR1 (0.68) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL5418343 0.85 ESR1 (0.61) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL28631452 0.84 ESR1 (0.57) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL14101079 0.84 ESR1 (0.70) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL5359582 0.83 ESR1 (0.65) ESR1ESR2HDAC6HDAC8PKM
SCHEMBL21834082 0.82 ESR1 (0.57) ESR1ESR2HDAC6HDAC8PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723384-B2 Keto lactam compounds and use thereof ABBOTT GMBH & CO. KG. (DE) 2010-05-25 US disclosed
US-7465744-B2 Triazole compounds and the therapeutic use thereof ABBOTT GMBH & CO. KG (DE) 2008-12-16 US disclosed
EP-1594861-B1 TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF ABBOTT GMBH & CO KG (DE) 2008-06-18 EP disclosed
US-20070219182-A1 Keto Lactam Compounds and Use Thereof ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2007-09-20 US disclosed
US-20060241137-A1 Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2006-10-26 US disclosed
EP-1692129-A1 KETO LACTAM COMPOUNDS AND USE THEREOF Abbott GmbH & Co. KG (DE) 2006-08-23 EP disclosed
WO-2005056546-A1 KETO LACTAM COMPOUNDS AND USE THEREOF ABBOTT GMBH & CO. KG (DE) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241137-A1 Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline DRD3, SLC6A3, ADORA3 ESR1 1097/4885ESR2 1289/4885HDAC6 2902/4885
US-20070219182-A1 Keto Lactam Compounds and Use Thereof OPRD1, DRD3, OPRK1 ESR1 1470/4885ESR2 881/4885HDAC6 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.